The company hold 55 patents in "Methods and Compositions for Deterring Abuse of Opioid", or "Impede PSE Products".
It's been many years in the making. Currently, there is no large phama known in developing the technology. And the fact that PFE is ACUR's partner for the technology speaks volume.
I think a buyout isn't critical for this company, which has a rich pipeline, with products already in the market. I think the stock will be in $4-5 in the next week or so. A buyout could fetch $6, easily. Those patents took years and big money to develop.
Check your math. 45 M shares x 6 =270M . According to investor relations last years nominal sales resulted in no more than 30M, and better sales next year of Oxecta.Nominal of 30M x 20 life of one product patent is 600M or 12+ a share for "ONE" product, and their least productive. Nexafed is expected (Now pushed by FDA) to fetch 50M times 20 life of patent 1Billion conservatively.